From genes to drugs: Target validation in Caenorhabditis elegans

Drug Discovery Today: Technologies

Volumn 1, Issue 2, 2004, Pages 171-177

  Sluder, Ann E ^a   Baumeister, Ralf ^b  

^a Cambria Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOUBLE STRANDED RNA; DRUG; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CAENORHABDITIS ELEGANS; DRUG TARGETING; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC SCREENING; HUMAN; KNOCKOUT GENE; NONHUMAN; PROTEIN FUNCTION; RNA INTERFERENCE; TRANSGENICS; VALIDATION PROCESS;

EID: 13244284559     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2004.09.007     Document Type: Review

References (41)

1. C. elegans Sequencing Consortium Genome sequence of the nematode C. elegans: A platform for investigating biology Science 282 1998 2012-2018
2. R. Baumeister L. Ge The worm in us - Caenorhabditis elegans as a model of human disease Trends Biotechnol. 20 2002 147-148
3. W.B. Wood The Nematode Caenorhabditis elegans 1988 Cold Spring Harbor Laboratory Press
4. D.L. Riddle C. elegans II 1997 Cold Spring Harbor Laboratory Press
5. A. Gaud et al. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans Neuromuscul. Disord. 14 2004 365-370
6. J.G. Wood et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans Nature 430 2004 686-689
7. E.M. Link et al. Therapeutic target discovery using Caenorhabditis elegans Pharmacogenomics 1 2000 203-217
8. D.J. Matthews J. Kopczynski Using model-system genetics for drug-based discovery Drug Discovery Today 6 2001 141-149
9. R. Baumeister Cross-species studies for target validation Brief. Funct. Genom. 1 2002 53-65
10. R.R. Zwaal et al. Target-selected gene inactivation in Caenorhabditis elegans by using a frozen transposon insertion mutant bank Proc. Natl. Acad. Sci. USA 90 1993 7431-7435
11. L.X. Liu et al. High-throughput isolation of deletion mutants of C. elegans Genome Res. 9 1999 859-867
12. S. Paradis G. Ruvkun Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor Genes Dev. 12 1998 2488-2498
13. M. Hertweck et al. C. elegans SGK-1 is the critical component in the Akt/PKB kinase complex to control stress response and life span Dev. Cell 6 2004 577-588
14. A. Fire et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806-811
15. W.M. Winston et al. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1 Science 295 2002 2456-2459
16. H. Tabara et al. RNAi in C. elegans - soaking in the genome Science 282 1998 430-431
17. L. Timmons A. Fire Specific interference by ingested dsRNA Nature 395 1998 854
18. R.S. Kamath et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi Nature 421 2003 231-237
19. K. Ashrafi et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes Nature 421 2003 268-272
20. T. Vellai et al. Genetics: Influence of TOR kinase on lifespan in C. elegans Nature 426 2003 620
21. B. Meissner et al. Deletion of the intestinal peptide transporter affects insulin and TOR signaling in C. elegans J. Biol. Chem. 279 2004 36739-36745
22. F. Simmer et al. Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions PLoS Biol. 1 2003 E12
23. C. Mello A. Fire DNA transformation. In: H.F. Epstein D.C. Shakes (Eds.) Caenorhabditis elegans: Modern Biological Analysis of an Organism 1995 Academic Press 452-482
24. V. Praitis et al. Creation of low-copy integrated transgenic lines in Caenorhabditis elegans Genetics 157 2001 1217-1226
25. M.O. Hengartner et al. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 Cell 76 1994 665-676
26. B. Westlund et al. Invertebrate disease models in neurotherapeutic discovery Curr. Opin. Drug Discov. Dev. 7 2004 169-178
27. A.A. Hill et al. Genomic analysis of gene expression in C. elegans Science 290 2000 809-812
28. S.K. Kim et al. A gene expression map for Caenorhabditis elegans Science 293 2001 2087-2092
29. S. Li et al. A map of the interactome network of the metazoan C. elegans Science 303 2004 540-543
30. Walhout et al. Protein interaction mapping in C. elegans using proteins involved in vulval development Science 287 2000 116-122
31. A. Davy et al. A protein-protein interaction map of the Caenorhabditis elegans 26S proteasome EMBO Rep. 2 2001 821-828
32. J. Hodgkin Conventional genetics In I.A. Hope ed. C. elegans: A Practical Approach 1999 Oxford University Press 245-270
33. K.A. Swan et al. High-throughput gene mapping in Caenorhabditis elegans Genome Res. 12 2002 1100-1105
34. M. Driscoll B. Gerstbrein Dying for a cause: Invertebrate genetics takes on human neurodegeneration Nat. Rev. Genet. 4 2003 181-194
35. S. Ogg et al. The fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans Nature 389 1997 994-999
36. R. Baumeister The physiological role of presenilins in cellular differentiation: Lessons from model organisms Eur. Arch. Psychiatry Clin. Neurosci. 249 1999 280-287
37. R. Francis et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation Dev. Cell. 3 2002 85-97
38. R.K. Choy J.H. Thomas Fluoxetine-resistant mutants in C. elegans define a novel family of transmembrane proteins Mol. Cell. 4 1999 143-152
39. E. Braungart et al. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screening Neurodeg. Dis. 1 2004 175-183
40. L.S. Huang P.W. Sternberg Genetic dissection of developmental pathways Methods Cell Biol. 48 1995 97-122
41. J.B. Rand C.D. Johnson Genetic pharmacology: Interactions between drugs and gene products in Caenorhabditis elegans Methods Cell Biol. 48 1995 187-204